Skip to Content

National Graphite Corp NGRC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

National Graphite Corp is an American based biopharmaceutical risk/cost-sharing company. It engages in pursuing the commercial development of a drug candidate, Elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. It aims at developing drugs and treatments to address unmet medical needs to treat rare diseases.

Contact
PO Box 26496
Scottsdale, AZ, 85255
Sector Healthcare
Industry Biotechnology
Most Recent Earnings May 31, 2015
Fiscal Year End May 31, 2016
Stock Type Cyclical
Employees 1